- Home
- BCTXZ
as 10-17-2025 3:47pm EST
Stocks
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
| Founded: | N/A | Country: | Canada |
| Employees: | 12 | City: | WEST VANCOUVER |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BriaCell Therapeutics Corp. Warrant News
BCTXZ Breaking Stock News: Dive into BCTXZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
Simply Wall St.
4 months ago
Here's Why We're A Bit Worried About BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation
MT Newswires
4 months ago
BriaCell Up in U.S. Pre-market, as Data Safety Board Review Recommends Phase 3 Study Continues
GlobeNewswire
4 months ago
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire
5 months ago
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
MT Newswires
5 months ago
BriaCell Reports "Robust" Overall Survival and Clinical Benefit Data at ASCO 2025
GlobeNewswire
5 months ago
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
MT Newswires
5 months ago
BriaCell Down More Than 2% Even As Says Bria-OTS Phase 1/2 Study Clears Safety Evaluation; First Patient Dosed
Compare BCTXZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCTXZ BriaCell Therapeutics Corp. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.